| Company Announcements: (reported by the Company) |
No items found
|
| Elevator Pitch: | Invex Therapeutics (ASX: IXC) is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin‚Ñ¢. |
| Category: | Hardware & devices, Health & biotech |
| URL: | http://www.invextherapeutics.com |
| Operational Status: | |
| ASX Listing Code (if applicable): | |
| Year of Commencement: | 2019 |
| Address: | 38 Rowland Street, Subiaco, 6008, AU |
| State: | Western Australia |
| Overseas Operations: | |
| X: | |
| Facebook: | |
| Linkedin: | https://linkedin.com/company/invextherapeutics |
| Founders: |
No items found
|
| Awards won: | |
